AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8097114
Drug: Raclopride (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raclopride (all doses)
Trial: 2880747
Drug: Theophylline (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (plasma concentration 25-45 mumol/l)
Trial: 2880747
Drug: Theophylline (plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (plasma concentration 50-85 mumol/l)
Trial: 2880747
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mumol/l)
Trial: 23896317
Drug: High-frequency (HF)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency (HF) rTMS treatment
Trial: 1775263
Drug: Haemodialysis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemodialysis with desferrioxamine (1 g intravenously 24‐40 h before dialysis); n = 28
Trial: 1775263
Drug: Haemofiltration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemofiltration with desferrioxamine (1 g intravenously 24‐40 h before haemofiltration); n = 36
Trial: 6871055
Drug: 0.8% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.8% prilocaine (4 mg/kg body weight)
Trial: 6871055
Drug: 1.5% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5% prilocaine (4 mg/kg body weight)
Trial: 6871055
Drug: 2% prilocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% prilocaine (4 mg/kg body weight)
Trial: 31809905
Drug: Both dosing
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosing groups
Trial: 21365326
Drug: A2A2 genotype
RxNorm normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A2A2 genotype of the PIN3 (+16 bp) polymorphism in patients treated with chemotherapy without anthracycline
Trial: 17404368
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell support (AHPCS)
Trial: 17404368
Drug: Dose-dense and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose-dense and dose-escalated chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide
Trial: 15827104
Drug: Intravenous alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous alendronate (ALN) at a dose of 125 mcg
Trial: 15827104
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (ALN) 35 mg for patients weighing less than 40 kg
Trial: 15827104
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (ALN) 70 mg for patients weighing 40 kg or more
Trial: 15827104
Drug: Adverse experiences
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse experiences from single-dose ALN
Trial: 2529370
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at 1.2 pmol kg‐1 min‐1
Trial: 385398
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg daily
Trial: 373995
Drug: Ibuprofen 1200
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 1200 mg daily
Trial: 26575256
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 1200 mg/day
Trial: 26575256
Drug: Eslicarbazepine acetate
RxNorm normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eslicarbazepine acetate (ESL) 800 mg/day
Trial: 26575256
Drug: Combined ESL
RxNorm normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined ESL arms (800 and 1200 mg/day)
Trial: 20736382
Drug: Tailored Pro‐Self(©)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored Pro‐Self(©) exercise during and after chemotherapy
Trial: 19359920
Drug: Continuous bupivacaine
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bupivacaine infusion through thoracic epidural (TEA)
Trial: 19359920
Drug: Continuous bupivacaine
RxNorm normalized name: Uniphyllin Continus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous bupivacaine infusion through thoracic paravertebral block (TPVB)
Trial: 16309809
Drug: 375 mg
RxNorm normalized name: niacin 375 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg of E. amoenum aqueous extract
Trial: 11741108
Drug: Oral single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single-dose (20 mg) ketanserin
Trial: 8219660
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (9 g daily for 6 weeks)
Trial: 8219660
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (9 g daily for 6 weeks)
Trial: 24980467
Drug: MenACWY‐CRM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM vaccine (two‐ or three‐dose primary infant series plus a single toddler dose)
Trial: 24980467
Drug: MenACWY‐CRM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM vaccine (three‐dose infant primary series)
Trial: 24980467
Drug: MenACWY‐CRM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM vaccine (two‐dose toddler catch‐up series)
Trial: 24980467
Drug: MenACWY‐CRM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM vaccine with concomitant routine vaccines
Trial: 24980467
Drug: MenACWY‐CRM vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY‐CRM vaccine (three‐dose infant series)
Trial: 22234287
Drug: High-speed power
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-speed power training (40% to 75% of 1RM); 3 sets of 4-12 reps, countermovement jump, and 1.5 kg medicine ball throwing
Trial: 16996947
Drug: Piracetam (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (150 mg/kg daily; 300 mg/kg on the day of surgery, then orally 12 g/day up to 6 weeks after surgery)
Trial: 12974696
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (30-minute application)
Trial: 11004038
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (15-20 mL of 3% 2-chloroprocaine)
Trial: 11004038
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia (75 mg of subarachnoid procaine with 20 microg fentanyl)
Trial: 1330962
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg for three days)
Trial: 18341564
Drug: Lidocaine 5%
RxNorm normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine 5% gel
Trial: 26987963
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with conventional rehabilitation therapies
Trial: 26987963
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapies
Trial: 22486133
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine plus midazolam
Trial: 20451192
Drug: Combined approach
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined approach of diagnostic hysteroscopy and endometrial sampling during oral contraceptive pill treatment followed by ultrashort GnRH‐ag/GnRH‐ant protocol
Trial: 16138560
Drug: Candesartan (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (2 to 12 mg daily)
Trial: 11809430
Drug: Aspirin (acetylsalicylic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (acetylsalicylic acid [ASA], 1, 3, and 10 mg/min)
Trial: 6294796
Drug: Cefotaxime (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (20 mg/kg IV every 6 hr)
Trial: 6294796
Drug: Gentamicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin plus Clindamycin (1 mg/kg gentamicin IV every 8 hr plus 5 mg/kg clindamycin IV every 6 hr)
Trial: 31063870
Drug: Monthly Lessons
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Lessons (within RxWL patient platform)
Trial: 28504031
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% desoximetasone spray
Trial: 21175030
Drug: All buccal
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All buccal tubes
Trial: 17982122
Drug: Intra-patient dose
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-patient dose escalation of ipilimumab
Trial: 17982122
Drug: Prior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior therapy with IFNalpha-2b
Trial: 17982122
Drug: Prior high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior high-dose interleukin-2
Trial: 17982122
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of high-dose steroids for treatment-related toxicities
Trial: 11549530
Drug: Long-acting beta(2)-agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting beta(2)-agonists (formoterol) with inhaled corticosteroids
Trial: 11549530
Drug: Short-acting beta(2)-agonists
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting beta(2)-agonists (salbutamol)
Trial: 9740164
Drug: Multidose formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidose formulation of epoetin alfa
Trial: 9740164
Drug: Single-dose formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose formulation of epoetin alfa
Trial: 8113548
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/day for 2 weeks)
Trial: 3123540
Drug: Terbutaline 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline 0.1 mg/kg up to 4 mg
Trial: 3123540
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cromolyn and terbutaline
Trial: 29231470
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (yupingfeng granules prescribed for oral administration, three times a day for 2 months)
Trial: 26233501
Drug: TH/lidocaine (LD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%
Trial: 21641819
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) of remifentanil (target: 7 ng/mL)
Trial: 21641819
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion (CI) of remifentanil (0.3 μg/kg/min)
Trial: 10399633
Drug: Gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine (0.2‐mmol/kg intravenous bolus)
Trial: 2246974
Drug: met‐hGH (16.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: met‐hGH (16.0 mg/wk of Protropin)
Trial: 6258116
Drug: ACO II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACO II protocol (maintenance therapy after aggressive induction treatment)
Trial: 31090458
Drug: Bacillus subtilis
RxNorm normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacillus subtilis R0179 (2.5×10^9 cfu/capsule)
Trial: 31090458
Drug: Bifidobacterium animalis
RxNorm normalized name: Bifidobacterium Animalis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium animalis subsp. lactis B94 (5×10^9 cfu/capsule)
Trial: 27918846
Drug: Soy food
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy food consumption (2 daily servings)
Trial: 25191771
Drug: Rivastigmine treatment
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine treatment
Trial: 17886253
Drug: Atrasentan 10
RxNorm normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrasentan 10 mg per day
Trial: 15282985
Drug: Femoral nerve
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoral nerve block with 30 ml of ropivacaine 7.5 mg/ml
Trial: 15282985
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment only (Paracetamol and tramadol)
Trial: 17284249
Drug: Sildenafil (25,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (25, 50, and 100 mg)
Trial: 8003642
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg every morning and at bedtime
Trial: 2583918
Drug: Fluoxetine 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 10, 20, 40 mg
Trial: 31386273
Drug: Topiramate 125
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate 125 mg daily
Trial: 28357504
Drug: GAD-alum (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (two doses)
Trial: 28357504
Drug: GAD-alum (four
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GAD-alum (four doses)
Trial: 25998572
Drug: Extended-release aspirin
RxNorm normalized name: aspirin Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release aspirin (ER-ASA)
Trial: 25998572
Drug: Immediate-release aspirin
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate-release aspirin (IR-ASA)
Trial: 21859401
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (2080 mg daily for 10 weeks)
Trial: 18085141
Drug: Ear point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ear point taping and pressing therapy combined with acupoint-injection
Trial: 18085141
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine (medication group)
Trial: 15181487
Drug: Famciclovir 250
RxNorm normalized name: famciclovir 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famciclovir 250 mg thrice daily
Trial: 15181487
Drug: Acyclovir 800
RxNorm normalized name: acyclovir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 800 mg 5 times daily
Trial: 8083368
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg t.i.d.) during high salt diet
Trial: 10095796
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg once daily)
Trial: 26944023
Drug: Cenicriviroc (CVC)
RxNorm normalized name: salicylic acid
DrugBank: Cenicriviroc (DB11758)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cenicriviroc (CVC) 150 mg
Trial: 24913131
Drug: IPL-PDT using
RxNorm normalized name: IPL-344
DrugBank: IPL-344 (DB16958)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPL-PDT using 0.5% 5-aminolevulinic acid liposomal spray
Trial: 15472496
Drug: Calcium antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonist
Trial: 15472496
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blocker
Trial: 11379373
Drug: Isoflavone-free, isocaloric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone-free, isocaloric placebo preparation
Trial: 8556225
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg twice daily for 12 weeks
Trial: 8299854
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg once daily for 12 weeks
Trial: 8299854
Drug: Ketanserin plus
RxNorm normalized name: ketanserin
DrugBank: Ketanserin (DB12465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin plus Enalapril (both at original dosage) for 12 weeks
Trial: 31852650
Drug: Early physical
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early physical therapy
Trial: 3526267
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (infants weighing less than 750 g at birth)
Trial: 28834191
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with fractional CO2 laser and PRP
Trial: 28834191
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with fractional CO2 laser and NB-UVB
Trial: 20482537
Drug: Uterine artery
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uterine artery Doppler test combined with aspirin treatment
Trial: 16026136
Drug: Probiotic strain
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic strain Enterococcus faecium M-74 (2x10^9 CFU) plus 50 microg of selenium, administered daily for 56 weeks
Trial: 12488294
Drug: Letrozole 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 1.0 mg once daily
Trial: 12488294
Drug: Fadrozole 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole 1.0 mg twice daily
Trial: 9093891
Drug: Polysulphone low-flux
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysulphone low-flux dialyzers (F6HPS) rinsed with 1000 ml of saline plus 2000 IU of heparin
Trial: 9093891
Drug: Polysulphone high-flux
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polysulphone high-flux dialyzers (F6OS) rinsed with 1000 ml of saline plus 2000 IU of heparin
Trial: 9093891
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups rinsed with 500 ml of saline without heparin
Trial: 8425280
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment
Trial: 31722605
Drug: Lumpectomy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumpectomy plus radiotherapy and hormone therapy
Trial: 18753076
Drug: Continuous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous propofol infusion via the common carotid artery (IC group, n=20)
Trial: 18753076
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol infusion via the median cubital vein (IV group, n=20)
Trial: 7702019
Drug: Nonlactating women
RxNorm normalized name: Arthricare for Women Moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlactating women and never pregnant women using oral contraceptives
Trial: 22001875
Drug: Adjuvanted 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted 2.5 μg RRV vaccine
Trial: 22001875
Drug: All vaccine
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccine formulations and doses
Trial: 15624747
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream
Trial: 15624747
Drug: Adapalene and
RxNorm normalized name: Adapalene and Benzoyl Peroxide Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapalene and tretinoin microsponge gels
Trial: 15624747
Drug: Tazarotene cream
RxNorm normalized name: Tazarotene Cream
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene cream and adapalene creams
Trial: 9204091
Drug: Adapalene gel
RxNorm normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene gel
Trial: 15624747
Drug: Vehicle (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (gel vs cream)
Trial: 11380642
Drug: Almotriptan (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almotriptan (various doses 2-150 mg)